Autolus Therapeutics 株価情報 (NASDAQ: AUTL)

最新ニュース Autolus Therapeutics (NASDAQ:AUTL) 株価情報

AUTOLUS THERAPEUTICS PLC

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics PLC

Austal Ltd

News

ODYS

Odysight.AI Joins Russell Microcap Index

Keybanc analyst Ken Newman maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Overweight and raises the price target from $150 to $155.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Emerson Electric, Raises Price Target to $155

Keybanc analyst Todd Thomas maintains Americold Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) with a Overweight and lowers the price target from $30 to $23.

COLD

Keybanc Maintains Overweight on Americold Realty Trust, Lowers Price Target to $23

WIIM

Warner Bros. Discovery shares are trading lower after the company disclosed via a 13D filing that A/NPP Diversified Holdings sold 100 million shares of stock, reducing its stake to 3.97%.

Additional Units Set for Delivery in Coming Days, Weeks, and Months
HOUSTON, TX / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 1, 2025 / Envirotech Vehicles, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) ("Envirotech," "EVT", or the "Company") is excited to announce the initiation of full commercial-stage operations in the Company's electric school bus vertical with its first three deliveries of its EVT Bumble Bee electric school bus to the independent school districts of Freer, Blanket, and Waelder, Texas.
Funding for the buses is provided by the United States Environmental Protection Agency ("EPA") as part of the Clean School Bus ("CSB") Program. The purpose of the CSB Program is to provide $5 billion over five years (FY 2022-2026) to replace existing school buses with zero-emission and clean school buses.
Under the CSB Program, Envirotech expects to deliver 25 total electric buses to school districts in Texas and Arkansas, with an aggregate of $8,570,000 awarded under the CSB Program to support these deliveries.
Management expects to deliver an additional EVT "Bumble Bee" electric school bus this week to another Texas independent school district. The EVT fast charging 100% electric school buses being delivered get up to 150 miles range and have zero emissions and zero noise pollution.
The Bumble Bee offers significant benefits over conventional fossil fuel powered buses:
Zero tailpipe emissions-students, drivers, and members of the community will be exposed to significantly less harmful diesel emissions like particulate matter and nitrogen oxides.
Reduced greenhouse gas emissions compared to diesel school buses.
Reduced maintenance costs due to: regenerative braking, no engine or exhaust system.
Potential for reduced fuel costs compared to diesel depending on electricity costs.
Quiet, clean operation.

Contracts

EVTV

Envirotech Vehicles Launches Full-Scale Electric School Bus Operations, Funded By $8.57M In EPA Clean School Bus Program For 25 Bus Deliveries In Texas And Arkansas

<a href="https://www.bloomberg.com/news/articles/2025-07-01/bessent-says-us-hopes-to-see-china-magnets-flow-at-faster-rate?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-07-01/bessent-says-us-hopes-to-see-china-magnets-flow-at-faster-rate?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-01/bessent-says-us-hopes-to-see-china-magnets-flow-at-faster-rate?srnd=homepage-americas</a>

Macro Economic Events

Economics

Bloomberg: 'Bessent Says US Hopes to See China Magnets Flow at 'Faster Rate''

The Centers for Medicare &amp; Medicaid Services (CMS) released a proposed rule on Monday outlining changes to how Medicare pays home health agencies (HHAs) in <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">calendar year (CY) 2026</a>.
These updates are required by law and occur annually.
The <a target="_blank" href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-home-health-prospective-payment-system-proposed-rule-fact-sheet-cms-1828-p#:~:text=For%20the%20CY%202026%20HH,30%2Dday%20base%20payment%20rate." rel="noreferrer noopener">rule</a> includes a routine payment increase of 2.4%, which would add about $425 million in funding. However, three other proposed changes would reduce payments:
<ul class="wp-block-list">
<li>A permanent behavior adjustment would cut payments by about 3.7% ($655 million),</li>
<li>A temporary adjustment would reduce payments by 4.6% ($815 million),</li>
<li>A change to the outlier payment formula (FDL ratio) would result in an additional 0.5% ($90 million) reduction.</li>
</ul>
Overall, CMS estimates that total Medicare payments to home health agencies in 2026 will decrease by 6.4%, or approximately $1.135 billion, compared to 2025.
<h2 class="wp-block-heading">Stock In Focus</h2>
Specific to its coverage, William Blair notes that home health accounts for roughly 5% of Addus HomeCare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) revenue and roughly 63% of Amedisys Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) revenue (Amedisys is in the <a href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape" target="_blank" rel="noreferrer noopener">process of being</a> acquired by UnitedHealth Inc&#8216;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>) Optum.
<h2 class="wp-block-heading">Addus HomeCare</h2>
&#8220;In our view, Addus presents one of the few opportunities for public equity investors to gain exposure to the in-home care delivery theme, with a particular emphasis on nonmedical care,&#8221; William Balir wrote in an investor note on Monday.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42515091/home-based-health-service-provider-addus-homecare-is-well-positioned-to-grow-analyst" rel="noreferrer noopener">As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst</a>
Analyst Matt Larew views the company's differentiated position in the marketplace as supporting strong growth characteristics, which are expected to be at the high end of management's typical 3% to 5% organic baseline target. William Blair maintains an Outperform rating.
<h2 class="wp-block-heading">Amedisys</h2>
&#8220;We believe that Amedisys is well-positioned to take advantage of strong secular tailwinds that should support total volume growth in the company's markets (home health, hospice, and personal care) at least in the mid single digits for the next decade-plus,&#8221; the analyst wrote.
Amedisys' focus on quality and its well-rounded approach to in-home care position it to benefit more than most from the market's growth. However, in the short term, its stock will likely be influenced by labor trends, hospice recovery, home health payments, and the growth of its Contessa unit.
Looking further ahead, Amedisys is on track to become a top player in aging-in-place care. Through its mix of clinical expertise, technology, and on-the-ground staff, it will help insurers reduce costs and improve patient outcomes.
Price Action: ADUS closed at $115.19 on Monday. AMED stock is down 0.2% at $98.11 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46109624/rfk-jr-overhauls-cdc-vaccine-panel-sparking-expert-backlash-boycott-from-top-medical-group" target="_blank" rel="noreferrer noopener">RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Government

Regulations

Health Care

General

ADUS

AMED

Home Health Braces For Potential $1 Billion Cut In Medicare Payments

Insider Trades

Warner Bros. Discovery 13D Amended Filing Shows A/NPP Diversified Holdings LLC Sells 100M Warner Bros. Discovery Shares, Reducing Stake To 3.97% As Of June 30, 2025

Chardan Capital analyst James McIlree initiates coverage on Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) with a Buy rating and announces Price Target of $15.

Initiation

Chardan Capital Initiates Coverage On Urgently with Buy Rating, Announces Price Target of $15

GPUS

Hyperscale Data shares are trading higher after the company announced its subsidiary will launch a decentralized cryptocurrency exchange.

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) (BMV:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#BMV">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces its ZenaDrone subsidiary has submitted the Green UAS (Unmanned Aerial Systems) application for the IQ Nano drone enabling it to be added to the pre-approved procurement list for US Defense and government buyers. In addition, the ZenaTech also closed of its sixth US land survey company acquisition with is an essential part of its national Drone as a Service -- or DaaS -- rollout.
Achieving Green UAS certification takes several months according to the <a href="https://www.globenewswire.com/Tracker?data=PIAsF7PwDSmRxJx0qkKTs0cD_leo52J3RnhnYRxHvlt8plZvY2TnM02lNGm2BqL3bUcc0CqNdbGEe3EJKQmsyQ==">AUVSI</a> drone association which administers it. Green UAS is a requirement by government buyers that must have secure and non-Chinese systems. Considered a steppingstone to <a href="https://www.globenewswire.com/Tracker?data=_dquOHw_F-6YFtwl0tKF7q8xXBzOHEcJdKkon9EC2o4icfW9KKr1A-5p_LMiXULr9jrm3NMnL1RKBtB9ywPvJA==">Blue UAS</a>, a Department of Defense certification the company plans to apply for next, it is required for sensitive government and military facilities that must have the next level of strict cybersecurity, supply chain, and operational standards.

BMV:ZENA

ZENA

ZenaTech's ZenaDrone Applies For Green UAS Certification, Advances U.S. Defense Access; Acquires Sixth Land Survey Firm For National DaaS Expansion, No Financial Terms Disclosed

Cohen &amp; Company Securities, LLC is pleased to announce that it has changed its name from J.V.B. Financial Group, LLC to Cohen &amp; Company Securities, LLC effective today.
The broker-dealer's name change supports efforts to create a consistent brand that is more closely aligned with its parent company, Cohen &amp; Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHN#NYSE">COHN</a>) ("Cohen"), and Cohen's other subsidiaries, in order to leverage the strength of the Cohen &amp; Company name and reputation for providing industry leading financial services.

COHN

J.V.B. Financial Group LLC Changes Name To Cohen & Company Securities LLC

TRNR

Interactive Strength shares are trading higher after the company completed the acquisition of Wattbike.

ECDA

ECD Automotive Design shares are trading higher after the company won national awards for custom Jaguar E-Type and Ford Mustang builds.

NIVF

Newgenlvf Group shares are trading higher after the company announced that its subsidiary secured strategic land in the UAE for its Blockchain initiative.

CAPS

Capstone Signs LOI To Acquire Southeast Stone Co.; Says 'purchase price is in line with the formula presented to investors in the Company's investment thesis for tuck-in deals - 4x to 6x EBITDA with 20% to 45% non-cash consideration'

SNGX

Soligenix shares are trading higher after the company announced it successfully completed the manufacturing process of synthetic hypericin to Sterling Pharma Solutions.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

GAME

GameSquare To Launch Ethereum-Native Yield Strategy As Part Of Treasury Initiative

Wattbike acquisition is the latest milestone in transformational strategy and the Sportstech acquisition is on track to close in the third quarter
TRNR confirms guidance of more than $75 million in pro forma 2025 revenue and profitability in fourth quarter
TRNR's $55 million Digital Asset Treasury is actively purchasing $FET cryptocurrency
AUSTIN, TX AND NOTTINGHAM, UK / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 1, 2025 / Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech, today announced that it has completed its previously announced all-stock acquisition of Wattbike, the pioneering indoor performance training bike business trusted by elite athletes and fitness enthusiasts worldwide, which has cumulatively sold more than 100,000 bikes.
The closing follows the approval on June 18, 2025 from the UK Financial Conduct Authority and the satisfaction of all material conditions of the binding transaction agreement signed in April 2025. Wattbike's operations will be consolidated into TRNR's results immediately and will be reported in TRNR's third quarter financials.

Guidance

Interactive Strength Completes Wattbike Acquisition; Reaffirms $75M Revenue Guidance And Q4 Profitability; Actively Investing in $FET Crypto

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and maintains $98 price target.

USPH

Barrington Research Maintains Outperform on US Physical Therapy, Maintains $98 Price Target

Press Releases

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Comments

Autolus Therapeutics

ニュース

最新ニュース Autolus Therapeutics (NASDAQ:AUTL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル